Minerva Neurosciences Inc (NERV) - Total Liabilities

Latest as of September 2025: $62.67 Million USD

Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has total liabilities worth $62.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Minerva Neurosciences Inc to assess how effectively this company generates cash.

Minerva Neurosciences Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Minerva Neurosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Minerva Neurosciences Inc to evaluate the company's liquid asset resilience ratio.

Minerva Neurosciences Inc Competitors by Total Liabilities

The table below lists competitors of Minerva Neurosciences Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Carmit TA:CRMT	Israel	ILA202.22 Million
Lithium Energy Ltd AU:LEL	Australia	AU$2.64 Million
Korea Bio-Gen Co.Ltd KQ:318000	Korea	₩4.38 Billion
Dare Bioscience Inc NASDAQ:DARE	USA	$29.63 Million
Gurktaler AG ST VI:GAGS	Austria	€568.00K
Daesung Eltec Co. Ltd KQ:025440	Korea	₩292.76 Billion
India Globalization Capital Inc NYSE MKT:IGC	USA	$1.65 Million
FN REPUBLIC Co. Ltd KQ:064090	Korea	₩3.75 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Minerva Neurosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Minerva Neurosciences Inc.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.81	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	2.23	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Minerva Neurosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Minerva Neurosciences Inc (2012–2024)

The table below shows the annual total liabilities of Minerva Neurosciences Inc from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	$62.84 Million	-26.38%
2023-12-31	$85.36 Million	+13.64%
2022-12-31	$75.11 Million	+8.63%
2021-12-31	$69.15 Million	+1293.06%
2020-12-31	$4.96 Million	-90.02%
2019-12-31	$49.72 Million	+1.74%
2018-12-31	$48.87 Million	-6.20%
2017-12-31	$52.10 Million	+93.25%
2016-12-31	$26.96 Million	-1.09%
2015-12-31	$27.26 Million	+60.80%
2014-12-31	$16.95 Million	+88.44%
2013-12-31	$9.00 Million	+4627.09%
2012-12-31	$190.29K	--

About Minerva Neurosciences Inc

NASDAQ:NERV USA Biotechnology

Market Cap

$42.45 Million

Market Cap Rank

#24065 Global

#4961 in USA

Share Price

$6.07

Change (1 day)

-6.18%

52-Week Range

$1.38 - $8.07

All Time High

$117.60